Publications by authors named "Inese Cebere"
A double-blind randomized phase I trial was conducted in human immunodeficiency virus type 1 (HIV-1)-negative subjects receiving vaccines vectored by plasmid DNA and modified vaccinia virus Ankara (MVA) expressing HIV-1 p24/p17 gag linked to a string of CD8(+) T-cell epitopes. The trial had two groups. One group received either two doses of MVA.
View Article and Find Full Text PDFArticle Synopsis
- Researchers conducted phase I trials in Oxford, UK, testing two candidate vaccines (pTHr.HIVA DNA and MVA.HIVA) against HIV-1 in healthy adults.
- Both vaccines were found to be safe and well-tolerated, with no serious adverse events reported during the 6-month study period or up to 2 years post-vaccination.
- The results showed potential for further testing in larger phase I/II studies, as most participants experienced minor local reactions without severe symptoms.
In view of the global emergency posed by lack of access to highly active antiretroviral therapy (HAART) and the limitations of current drug regimens, alternative therapeutic strategies are urgently needed. Cellular immune responses elicited by HIV-1 exert some control over virus replication, therefore the enhancement of HIV-1-specific responses by therapeutic vaccination might lead to viral containment without HAART. We evaluated the safety and immunogenicity, in HIV-1-infected individuals under HAART suppression, of a DNA vaccine, pTHr.
View Article and Find Full Text PDFArticle Synopsis
- The study tested two types of HIV vaccines (DNA and modified vaccinia virus) in healthy volunteers in the UK to assess their ability to activate the immune response.
- Both vaccines focused on boosting cell-mediated immunity by using a common component called HIVA, which includes important proteins and epitopes for targeting HIV.
- Results showed that both vaccines were safe and successfully elicited HIV-specific immune responses in most participants, which supports continuing the development of these vaccines.